Reprogrammed cells for disease modeling and regenerative medicine

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 277-290

  Cherry, Anne B C ^a,c,e   Daley, George Q ^a,b,c,d,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

cellular therapy; gene correction; hematology; history of reprogramming; induced pluripotent stem (iPS) cells

Indexed keywords

ARTICLE; BLOOD; CELL THERAPY; EMBRYONIC STEM CELL; GENETIC DISORDER; HEMATOLOGIC DISEASE; HEMATOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VITRO STUDY; MEDICAL ETHICS; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; SCIENTIFIC LITERATURE; SOMATIC CELL;

CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TISSUE THERAPY;

EID: 84873025749     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050311-163324     Document Type: Article

References (69)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282:1145-47
2. Gottweis H, Prainsack B. 2006. Emotion in political discourse: contrasting approaches to stem cell governance in the USA, UK, Israel and Germany. Regenerative Med. 1:823-29
3. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-76
4. Davis RL, Weintraub H, Lassar AB. 1987. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51:987-1000
5. Wernig M, Meissner A, Foreman R, et al. 2007. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448:318-24
6. Okita K, Ichisaka T, Yamanaka S. 2007. Generation of germline-competent induced pluripotent stem cells. Nature 448:313-17
7. Zhao XY, Li W, Lv Z, et al. 2009. iPS cells produce viable mice through tetraploid complementation. Nature 461:86-90
8. Boland MJ, Hazen JL, Nazor KL, et al. 2009. Adult mice generated from induced pluripotent stem cells. Nature 461:91-94
9. Takahashi K, Tanabe K, Ohnuki M, et al. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-72
10. Yu JY, Vodyanik MA, Smuga-Otto K, et al. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-20
11. Park IH, Zhao R, West JA, et al. 2008. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451:141-46
12. Dimos JT, Rodolfa KT, Niakan KK, et al. 2008. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321:1218-21
13. Park IH, Arora N, Huo H, et al. 2008. Disease-specific induced pluripotent stem cells. Cell 134:877-86
14. Ben-David U, Benvenisty N. 2011. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 11:268-77
15. Zhao R, Daley GQ. 2008. From fibroblasts to iPS cells: induced pluripotency by defined factors. J. Cell. Biochem. 105:949-55
16. Nishikawa S, Goldstein RA, Nierras CR. 2008. The promise of human induced pluripotent stem cells for research and therapy. Nat. Rev. Mol. Cell Biol. 9:725-29
17. Lerou PH, Daley GQ. 2005. Therapeutic potential of embryonic stem cells. Blood Rev. 19:321-31
18. Gore A, Li Z, Fung HL, et al. 2011. Somatic coding mutations in human induced pluripotent stem cells. Nature 471:63-67
19. Hussein SM, Batada NN, Vuoristo S, et al. 2011. Copy number variation and selection during reprogramming to pluripotency. Nature 471:58-62
20. Alikani M, Munne S. 2005. Nonviable human pre-implantation embryos as a source of stem cells for research and potential therapy. Stem Cell Rev. 1:337-43
21. Tropel P, Tournois J, Come J, et al. 2010. High-efficiency derivation of human embryonic stem cell lines following pre-implantation genetic diagnosis. In Vitro Cell. Dev. Biol. Anim. 46:376-85
22. Cherry ABC, Daley GQ. 2012. Reprogramming cellular identity for regenerativemedicine. Cell 148:1110-22
23. Kim K, Doi A, Wen B, et al. 2010. Epigeneticmemory in induced pluripotent stem cells. Nature 467:285-90
24. Polo JM, Liu S, Figueroa ME, et al. 2010. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28:848-55
25. Chin MH, Mason MJ, Xie W, et al. 2009. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5:111-23
26. Doi A, Park IH, Wen B, et al. 2009. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41:1350-53
27. Guenther MG, Frampton GM, Soldner F, et al. 2010. Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell 7:249-57
28. Thomas ED, Lochte HL, Cannon JH, et al. 1959. Supralethal whole body irradiation and isologous marrow transplantation in man. J. Clin. Invest. 38:1709-16
29. Thomas ED, Storb R, Clift RA, et al. 1975. Bone-marrow transplantation. Part 1. N. Engl. J. Med. 292:832-43
30. Copelan EA. 2006. Medical progress: hematopoietic stem-cell transplantation. N. Engl. J.Med. 354:1813-26
31. Martino R, Iacobelli S, Brand R, et al. 2006. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using BLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836-46
32. Goerner M, Gooley T, Flowers MED, et al. 2002. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patientswith aplastic or refractory anemias. Biol. Blood Marrow Transplant. 8:47-56
33. Stern M, Passweg JR, Locasciulli A, et al. 2006. Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation 82:218-26
34. Bai LY, Chiou TJ, Liu JH, et al. 2004. Hematopoietic stem cell transplantation for severe aplastic anemia- experience of an institute in Taiwan. Ann. Hematol. 83:38-43
35. Maury S, Bacigalupo A, Anderlini P, et al. 2009. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Hematologica 94:1312-15
36. Medvinsky A, Dzierzak E. 1996. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86:897-906
37. Muller AM, Medvinsky A, Strouboulis J, et al. 1994. Development of hematopoietic stem-cell activity in the mouse embryo. Immunity 1:291-301
38. Chen MJ, Yokomizo T, Zeigler BM, et al. 2009. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 457:887-91
39. Bertrand JY, Chi NC, Santoso B, et al. 2010. Haematopoietic stem cells derive directly from aortic endothelium during development. Nature 464:108-11
40. Kissa K, Herbomel P. 2010. Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature 464:112-15
41. Kumaravelu P, Hook L, Morrison AM, et al. 2002. Quantitative developmental anatomy of definitive haematopoietic stem cells long-term repopulating units (HSC/RUs): role of the aorta-gonad-mesonephros (AGM) region and the yolk sac in colonisation of the mouse embryonic liver. Development 129:4891-99
42. Gekas C, Dieterlen-Lievre F, Orkin SH, Mikkola HKA. 2005. The placenta is a niche for hematopoietic stem cells. Dev. Cell 8:365-75
43. Christensen JL, Wright DE, Wagers AJ, et al. 2004. Circulation and chemotaxis of fetal hematopoietic stem cells. PLOS Biol. 2:368-77
44. Ledran MH, Krassowska A, Armstrong L, et al. 2008. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 3:85-98
45. Ng ES, Davis RP, Azzola L, et al. 2005. Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood 106:1601-3
46. Kyba M, Perlingeiro RCR, Daley GQ. 2002. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 109:29-37
47. Pilat S, Carotta S, Schiedlmeier B, et al. 2005. HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. Proc. Natl. Acad. Sci. USA 102:12101-6
48. Wang Y, Yates F, Naveiras O, et al. 2005. Embryonic stem cell-derived hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 102:19081-86
49. Bowles KM, Vallier L, Smith JR, et al. 2006. HOXB4 overexpression promotes hematopoietic development by human embryonic stem cells. Stem Cells 24:1359-69
50. Wang LS, Menendez P, Shojaei F, et al. 2005. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J. Exp. Med. 201:1603-14
51. Ji J, Vijayaragavan K, Bosse M, et al. 2008. OP9 stroma augments survival of hematopoietic precursors and progenitors during hematopoietic differentiation from human embryonic stem cells. Stem Cells 26:2485-95
52. Rideout WM, Hochedlinger K, KybaM, et al. 2002. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 109:17-27
53. Hanna J, Wernig M, Markoulaki S, et al. 2007. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318:1920-23
54. Campbell KHS, McWhir J, Ritchie WA, Wilmut I. 1996. Sheep cloned by nuclear transfer from a cultured cell line. Nature 380:64-66
55. Warren L, Manos PD, Ahfeldt T, et al. 2010. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618-30
56. Okita K, Matsumura Y, Sato Y, et al. 2011. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8:409-12
57. Fusaki N, Ban H, Nishiyama A, et al. 2009. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jap. Acad. Ser. B Phys. Biol. Sci. 85:348-62
58. Hockemeyer D, Soldner F, Beard C, et al. 2009. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27:851-57
59. Osafune K, Caron L, Borowiak M, et al. 2008. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat. Biotechnol. 26:313-15
60. Choi KD, Yu J, Smuga-Otto K, et al. 2009. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 27:559-67
61. Howe SJ, Mansour MR, Schwarzwaelder K, et al. 2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118:3143-50
62. Capecchi MR. 1989. Altering the genome by homologous recombination. Science 244:1288-92
63. Sebastiano V, Maeder ML, Angstman JF, et al. 2011. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 29:1717-26
64. Zou J, Mali P, Huang X, et al. 2011. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118:4599-608
65. Liu GH, Suzuki K, Qu J, et al. 2011. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 8:688-94
66. Zou JZ, Maeder ML, Mali P, et al. 2009. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5:97-110
67. Sun N, Liang J, Abil Z, et al. 2012. Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. Mol. Biosystems 8:1255-63
68. Christian M, Cermak T, Doyle EL, et al. 2010. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186:757-61
69. Cermak T, Doyle EL, Christian M, et al. 2011. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39:e82. Erratum 39:7879